Can Agenus turn botensilimab and balstilimab into a serious post-ICI liver cancer contender?
Post-ICI liver cancer has few strong options. Agenus’ BOT plus BAL data raise the next question: can durability survive larger trials?
Is botensilimab finally ready for a bigger melanoma spotlight? Agenus bets on ASCO 2026
Agenus will unveil first Phase 2 botensilimab melanoma data at ASCO 2026. Read why the update could reshape sentiment around its checkpoint platform.
What the Agenus-MiNK Therapeutics combination reveals about the next phase of GI cancer immunotherapy
Agenus brings botensilimab, balstilimab, and agenT-797 to AACR 2026. Read why this refractory GEC update matters and what risks remain.
What Agenus’ BOT and BAL biomarker work reveals about rescuing immunologically cold tumors
Agenus’ AACR-IO biomarker data reframes inflammation as a key determinant in cold tumor immunotherapy. Find out why this could reshape checkpoint strategies.